

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### VOLUNTARY ANNOUNCEMENT ACQUISITION OF SHARES BY DIRECTORS

This announcement is a voluntary announcement made by Ascentage Pharma Group International (the “**Company**”).

The Company was notified by (i) Dr. Wang Shaomeng (“**Dr. Wang**”), a non-executive director of the Company that, on April 2, 2024, he has acquired an aggregate of 130,000 ordinary shares of the Company (the “**Shares**”) on-market at a total consideration of approximately HK\$2,371,113 with an average price of approximately HK\$18.24 per Share, representing approximately 0.045% of the total issued share capital of the Company as at the date of this announcement; and (ii) Dr. Yang Dajun (“**Dr. Yang**”), an executive director and the chairman of the board of directors of the Company that, on April 3, 2024, he has acquired an aggregate of 100,000 Shares on-market at a total consideration of approximately HK\$1,794,570 with an average price of approximately HK\$17.95 per Share, representing approximately 0.034% of the total issued share capital of the Company as at the date of this announcement (collectively, the “**Acquisitions**”).

As at the date of this announcement, each of Dr. Wang and Dr. Yang is deemed to be interested in an aggregate of 64,585,929 Shares pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) through interest of controlled corporations, interests held jointly with other persons, interest of spouse and being the settlor of a discretionary trust (please refer to the section headed “Directors’ and Chief Executives’ Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations” in the interim report of the Company for the six months ended June 30, 2023 for further details). As such, following the completion of the Acquisitions, each of Dr. Wang and Dr. Yang will be deemed to be interested in an aggregate of 64,815,929 Shares, representing approximately 22.33% of the total issued share capital of the Company as at the date of this announcement.

As advised by each of Dr. Wang and Dr. Yang, the Acquisitions indicate their confidence in the prospects of the Company.

The Acquisitions were conducted in compliance with applicable laws, rules and regulations, including the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Company's own code of conduct regarding securities transactions, namely the policy on management of securities transactions by directors.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, April 3, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*